Skip to content
Edaravone
Radicava (edaravone) is a small molecule pharmaceutical. Edaravone was first approved as Radicava on 2017-05-05. It is used to treat amyotrophic lateral sclerosis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Radicava, Radicava ors
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Edaravone
Tradename
Company
Number
Date
Products
RADICAVAMitsubishi Tanabe PharmaN-209176 RX2017-05-05
2 products, RLD, RS
RADICAVA ORSMitsubishi Tanabe PharmaN-215446 RX2022-05-12
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
radicavaNew Drug Application2021-03-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
amyotrophic lateral sclerosisEFO_0000253D000690G12.21
Agency Specific
FDA
EMA
Expiration
Code
EDARAVONE, RADICAVA ORS, MITSUBISHI TANABE
2025-05-12NP
EDARAVONE, RADICAVA, MITSUBISHI TANABE
2024-05-05ODE*, ODE-144
Patent Expiration
Patent
Expires
Flag
FDA Information
Edaravone, Radicava Ors, Mitsubishi Tanabe
109873412039-11-01DP
112414162039-11-01DP
114784502039-11-01U-3468
ATC Codes
N: Nervous system drugs
— N07: Other nervous system drugs in atc
— N07X: Other nervous system drugs in atc
— N07XX: Other nervous system drugs in atc
— N07XX14: Edaravone
HCPCS
Code
Description
J1301
Injection, edaravone, 1 mg
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hereditary angioedemasD054179EFO_0004131—24—16
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Operative surgical proceduresD013514—2———2
AngioedemaD000799EFO_0005532T78.3—2———2
Hereditary angioedema types i and iiD056829—1———1
Surgical blood lossD016063—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular edemaD0082691————1
Retinal vein occlusionD012170EFO_1001157H34.811————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEDARAVONE
INNedaravone
Description
Edaravone is a pyrazolone that is 2,4-dihydro-3H-pyrazol-3-one which is substituted at positions 2 and 5 by phenyl and methyl groups, respectively. It has a role as a radical scavenger and an antioxidant.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC1=NN(c2ccccc2)C(=O)C1
Identifiers
PDB—
CAS-ID89-25-8
RxCUI1921877
ChEMBL IDCHEMBL290916
ChEBI ID31530
PubChem CID4021
DrugBankDB12243
UNII IDS798V6YJRP (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,847 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,353 adverse events reported
View more details